Cargando…

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

BACKGROUND: Subclassification of ovarian carcinomas can be used to guide treatment and determine prognosis. Germline and somatic mutations, loss of heterozygosity (LOH), and epigenetic events such as promoter hypermethylation can lead to decreased expression of BRCA1/2 in ovarian cancers. The mechan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Press, Joshua Z, De Luca, Alessandro, Boyd, Niki, Young, Sean, Troussard, Armelle, Ridge, Yolanda, Kaurah, Pardeep, Kalloger, Steve E, Blood, Katherine A, Smith, Margaret, Spellman, Paul T, Wang, Yuker, Miller, Dianne M, Horsman, Doug, Faham, Malek, Gilks, C Blake, Gray, Joe, Huntsman, David G
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2245962/ https://www.ncbi.nlm.nih.gov/pubmed/18208621 http://dx.doi.org/10.1186/1471-2407-8-17

Ejemplares similares

A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention
por: Hanley, Gillian E., et al.
Publicado: (2018)

Hereditary diffuse gastric cancer: association with lobular breast cancer
por: Schrader, Kasmintan A., et al.
Publicado: (2007)

Rare APC promoter 1B variants in gastric cancer kindreds unselected for fundic gland polyposis
por: Dixon, Katherine, et al.
Publicado: (2021)

Analysis of molecular inversion probe performance for allele copy number determination
por: Wang, Yuker, et al.
Publicado: (2007)

Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
por: Köbel, Martin, et al.
Publicado: (2008)

HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy
por: McAlpine, Jessica N, et al.
Publicado: (2009)

MicroRNA Profiling of BRCA1/2 Mutation-Carrying and Non-Mutation-Carrying High-Grade Serous Carcinomas of Ovary
por: Lee, Cheng-Han, et al.
Publicado: (2009)

High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays
por: Wang, Yuker, et al.
Publicado: (2009)

Allele quantification using molecular inversion probes (MIP)
por: Wang, Yuker, et al.
Publicado: (2005)

Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma
por: Prentice, Leah M, et al.
Publicado: (2007)

Histologic and Genotypic Characterization of Lung Cancer in the Inuit Population of the Eastern Canadian Arctic
por: Goss, Glenwood D., et al.
Publicado: (2022)

Absence of BRCA/FMR1 Correlations in Women with Ovarian Cancers
por: Gleicher, Norbert, et al.
Publicado: (2014)

Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation
por: Metcalfe, Kelly A, et al.
Publicado: (2007)

Prediction of epigenetically regulated genes in breast cancer cell lines
por: Loss, Leandro A, et al.
Publicado: (2010)

Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation
por: Pradhan, Manohar, et al.
Publicado: (2010)

Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors
por: Milne, Katy, et al.
Publicado: (2009)

Correction: Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors
por: Milne, Katy, et al.
Publicado: (2013)

A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation
por: Wiegand, Kimberly C, et al.
Publicado: (2014)

Genetic Screening for Familial Gastric Cancer
por: Oliveira, Carla, et al.
Publicado: (2004)

Low grade serous carcinoma of the peritoneum in a BRCA1 carrier previously diagnosed with a “low-grade serous tubal intra-epithelial carcinoma” (STIC) on risk reducing surgery
por: Chay, Wen Yee, et al.
Publicado: (2015)

Benign serous ovarian tumour: a redefining moment?
por: Hunter, Sally, et al.
Publicado: (2012)

Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation
por: Metcalfe, K A, et al.
Publicado: (2009)

Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes
por: Milne, Katy, et al.
Publicado: (2012)

Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis
por: Turashvili, Gulisa, et al.
Publicado: (2009)

Rapid evolution of BRCA1 and BRCA2 in humans and other primates
por: Lou, Dianne I, et al.
Publicado: (2014)

Gastric Cancer Risk and Pathogenesis in BRCA1 and BRCA2 Carriers
por: Buckley, Kole H., et al.
Publicado: (2022)

Can you believe your eyes?: over 250 illusions and other visual oddities
por: Block, Richard, J, et al.
Publicado: (1992)

Molecular Abnormalities in Ovarian Cancer Subtypes Other than High-Grade Serous Carcinoma
por: Gilks, C. Blake
Publicado: (2010)

Claudin 4 Is Differentially Expressed between Ovarian Cancer Subtypes and Plays a Role in Spheroid Formation
por: Boylan, Kristin L. M., et al.
Publicado: (2011)

Telomere Length Shows No Association with BRCA1 and BRCA2 Mutation Status
por: Killick, Emma, et al.
Publicado: (2014)

Tumor Suppressor Pten Inhibits Nuclear Accumulation of β-Catenin and T Cell/Lymphoid Enhancer Factor 1–Mediated Transcriptional Activation
por: Persad, Sujata, et al.
Publicado: (2001)

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
por: Hodgson, Darren R., et al.
Publicado: (2018)

The Oncogenic Roles of DICER1 RNase IIIb Domain Mutations in Ovarian Sertoli-Leydig Cell Tumors()()
por: Wang, Yemin, et al.
Publicado: (2015)

Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases
por: Rajput, Ashish B., et al.
Publicado: (2007)

BRCA1 and BRCA2 in breast cancer families from Wales: moderate mutation frequency and two recurrent mutations in BRCA1.
por: Lancaster, J. M., et al.
Publicado: (1998)

Germline CDH1 deletions in hereditary diffuse gastric cancer families
por: Oliveira, Carla, et al.
Publicado: (2009)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
por: Cline, Melissa S., et al.
Publicado: (2018)

Synchronous carcinomas of endometrium and ovary: A pragmatic approach
por: Blake Gilks, C., et al.
Publicado: (2018)

Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers
por: McCrorie, Alan D, et al.
Publicado: (2020)

Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain)
por: Blay, Pilar, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_oquhsjh1ttmimf571u88nes9l5